Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $47.30 Consensus Price Target from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has earned an average rating of “Buy” from the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $47.30.

A number of analysts recently weighed in on the stock. Lifesci Capital upgraded shares of Sutro Biopharma to a “strong-buy” rating in a research note on Friday, May 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Wednesday, August 5th. Stifel Nicolaus set a $48.00 price objective on shares of Sutro Biopharma and gave the company a “buy” rating in a research report on Friday, August 7th. Wedbush restated an “outperform” rating and issued a $60.00 price objective on shares of Sutro Biopharma in a report on Thursday, August 13th. Finally, Mizuho set a $50.00 price objective on shares of Sutro Biopharma and gave the stock an “outperform” rating in a research report on Thursday, April 30th.

Institutional Trading of Sutro Biopharma

A number of institutional investors have recently bought and sold shares of STRO. Bridgeway Capital Management LLC increased its holdings in shares of Sutro Biopharma by 232.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares during the last quarter. Invesco Ltd. lifted its stake in Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after purchasing an additional 53,390 shares during the last quarter. Cerity Partners LLC boosted its holdings in Sutro Biopharma by 169.9% in the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after purchasing an additional 66,372 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in Sutro Biopharma in the second quarter valued at approximately $82,000. Finally, State of Tennessee Department of Treasury purchased a new position in Sutro Biopharma in the fourth quarter valued at approximately $86,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Price Performance

STRO opened at $21.91 on Friday. Sutro Biopharma has a 12 month low of $7.15 and a 12 month high of $43.85. The stock has a market capitalization of $363.27 million, a price-to-earnings ratio of -1.98 and a beta of 1.55. The business has a fifty day moving average price of $26.64 and a 200 day moving average price of $26.16.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The business had revenue of $9.84 million during the quarter, compared to the consensus estimate of $11.96 million. On average, research analysts anticipate that Sutro Biopharma will post -8.41 earnings per share for the current year.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.